CCRB Logo

Trial History Detail on 2020-06-23

CUHK_CCT00439

2014-11-24

Prospective

KC/KE-14-0198/FR-2

Department of Ophthalmology and Visual Sciences, the Chinese University of Hong Kong

Department of Ophthalmology and Visual Sciences, the Chinese University of Hong Kong

Nil

Not Applicable

Ms. Jennifer Tsoi

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, 3/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon

39435818

jennifertsoi@cuhk.edu.hk

The Chinese University of Hong Kong

Hong Kong

Prof. Leung Christopher Kai Shun

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, 3/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon

39435846

cksleung@cuhk.edu.hk

The Chinese University of Hong Kong

Hong Kong

Progressive lamina cribrosa deformation – A biomarker for fast progressors in glaucoma?

Progressive lamina cribrosa deformation – A biomarker for fast progressors in glaucoma?

進展性篩板變形–診斷青光眼快速進展者的新指標?

Nil

Hong Kong

Yes

2014-11-20

Kowloon Central Cluster REC / Kowloon East Cluster REC

KC/KE-14-0198/FR-2

Glaucoma

Other

Drug and Procedure

The intervention is to use additional eye drops and/or laser procedure to achieve 20% intraocular pressure (IOP) lowering from baseline.
Drug: prostaglandin analogue, brimonidine and carbonic anhydrase inhibitor
Procedure: Selective Laser Trabeculoplasty

Eyedrop or laser procedure

every two months

Drug: prostaglandin analogue (PGA, once daily), brimonidine (three times daily), carbonic anhydrase

every two months

The comparative treatment is to continue the current treatment (observation or one topical IOP lowering medication) started before recruitment (see Inclusion Criteria).

NA (depends on the current treatment)

NA (depends on the current treatment)

every three months

NA (depends on the current treatment)

1. Age ≥18 years
2. Best corrected visual acuity (VA) ≥20/40
3. POAG diagnosed at least 36 months
4. Participants are the ongoing participants under “Diagnostic Imaging Assessment in the Evaluation of Glaucomatous Optic Neuropathy and diagnosed with glaucoma “ study at Hong Kong Eye Hospital and have been followed up for at least 36 months.

1. IOP >30mmHg measured at any time points during the baseline visit
2. High myopia (spherical error<-6.0D)
3. Advanced VF loss (VF MD <-12dB in the worse eye) or defects close to fixation (any one of the paracentral points with sensitivity <10dB)
4. Inability to perform reliable VF; suboptimal quality of SDOCT images
5. Previous intraocular surgery other than uncomplicated cataract extraction
6. Diabetic retinopathy/maculopathy

18

999

Both Male and Female

Interventional

Randomized

Randomized to receive additional IOP lowering treatment or continue the current treatment

Active

Open label

Parallel

Other

N/A

2014-12-01

168

Recruiting

Proportion of eyes with VF progression

Proportion of eyes with RNFL progression
Rate of change visual field index
Rate of change of LC deformation before and after IOP reduction
Risk factors of LC deformation

No

2020-07-13

ChiCTR-IOR-14005592 

2014-12-03

Type Access Document Published On  
No documents yet.
  • Page 1 of 1.